Different Exercising Intensities and Frequencies of Exercise on Depressive Mood and Insomnia

Sponsor
The University of Hong Kong (Other)
Overall Status
Completed
CT.gov ID
NCT04354922
Collaborator
(none)
75
1
5
33
2.3

Study Details

Study Description

Brief Summary

Aerobic exercise intervention for depression was conventionally recommended three times weekly with moderate intensity in previous studies, but little is known about the training effect of aerobic exercise at low frequency and vigorous intensity. The purpose of this study is to compare the training effect of aerobic exercise at different exercising frequencies and intensities on older adults with comorbid insomnia and depressive symptoms. In this study, the investigators will investigate two types of aerobic exercise (i.e., vigorous-intensity exercise and moderate-intensity exercise) under different exercising frequencies (i.e., regular exercising pattern and weekend warrior). Individuals with chronic insomnia and depressive symptoms will be recruited and randomly allocated into 5 groups: 1) attention control group (stretching exercise), 2) moderate intensity exercise performed thrice weekly (MIE×3/wk), 3) moderate intensity exercise performed once weekly (MIE×1/wk), 4) vigorous intensity exercise performed thrice weekly (VIE×3/wk), and 5) vigorous intensity exercise performed once weekly (VIE×1/wk). Intervention will be maintained for 12 weeks. Outcome assessments will be conducted at baseline, 6 weeks and 12 weeks after the intervention. Outcomes including depressive status, chronic insomnia, objective sleep quality and pattern (measured by Actigraphy), subjective sleep quality (measured by Epworth sleepiness scale, insomnia severity index, PSQI), anxiety status (measured by HADS and GAD-7), quality of life (measured by SF-12), attention level (measured by computer attention test), exercise enjoyment (measured by physical activity enjoyment scale), habitual physical activity level (measured by IPAQ), aerobic fitness (measured by metabolic cart), body adiposity (measured by DXA), blood chemistry, adherence, medication usage, and adverse events will be measure in this study. This proposed study will provide pilot evidence for the benefits, effectiveness, safety, adherence, and sustainability of low-frequency vigorous aerobic exercise. the investigators expect the low-frequency exercise modality will enhance the practical suitability of aerobic exercise and will provide evidence for weekend warrior aerobic training strategy as a new exercise option in the management of elderly insomnia and depression.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Exercise intervention
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
75 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
5 groups ×2 times factorial design5 groups ×2 times factorial design
Masking:
Single (Outcomes Assessor)
Masking Description:
Single-blind (Outcome Assessor)
Primary Purpose:
Treatment
Official Title:
Effects of Different Exercising Intensities and Frequencies of Walking Exercise on Depressive Mood and Insomnia in Older Adults
Actual Study Start Date :
Jan 31, 2019
Actual Primary Completion Date :
Sep 30, 2021
Actual Study Completion Date :
Oct 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Attention control

Subjects in this group will receive one session of 75 minutes stretching exercise per week throughout the 12 weeks experimental period

Behavioral: Exercise intervention
Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.

Active Comparator: Moderate-intensity walking exercise ×3/wk

Subjects in this group will receive three sessions of 50 minutes vigorous walking exercise per week throughout the 12 weeks experimental period

Behavioral: Exercise intervention
Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.

Active Comparator: Moderate-intensity walking exercise ×1/wk

Subjects in this group will receive one session of 150 minutes vigorous walking exercise per week throughout the 12 weeks experimental period

Behavioral: Exercise intervention
Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.

Active Comparator: Vigorous-intensity walking exercise ×3/wk

Subjects in this group will receive three sessions of 25 minutes vigorous walking exercise per week throughout the 12 weeks experimental period

Behavioral: Exercise intervention
Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.

Active Comparator: Vigorous-intensity walking exercise ×1/wk

Subjects in this group will receive one session of 75 minutes vigorous walking exercise per week throughout the 12 weeks experimental period

Behavioral: Exercise intervention
Subjects in attention control group will receive one session of 75 minutes of stretching exercise weekly. All walking exercise session will be performed on motor-driven treadmill. Subjects in moderate-intensity walking groups will walk at an intensity of 3.25 metabolic equivalents (METs). Subjects in vigorous-intensity walking groups will brisk walk at an intensity of 6.5 metabolic equivalents (METs). Warm-up and cool-down will be provided before and after the training. Participants who failed to achieve 80% attendance will be excluded from the study. All exercise sessions were supervised by qualified athletic coach.

Outcome Measures

Primary Outcome Measures

  1. Level of depression [After completion of the 12 weeks intervention]

    Hospital Anxiety and Depression Scale (HADS) will be used to measure the level of depression

  2. Remission rate of insomnia [After completion of the 12 weeks intervention]

    Brief insomnia questionnaire (BIQ) will be employed to diagnose the chronic insomnia based on the DSM-5 criteria.

Secondary Outcome Measures

  1. Subjective sleep data [After completion of the 12 weeks intervention]

    The Epworth sleepiness scale, insomnia severity index, and Pittsburgh sleep quality index (PSQI) will be used to measure the sleep quality.

  2. Objective sleep data [After completion of the 12 weeks intervention]

    Actigraphy will be used to measure the sleep quality and pattern.

  3. Change in dose of Sleep Medication [After completion of the 12 weeks intervention]

    The dose of sleep medication used by the subjects changes after intervention.

  4. 7-day Sleep Diary [After completion of the 12 weeks intervention]

    Self-recorded sleep parameters (sleep onset latency, sleep efficiency, total sleep time, wake time after sleep onset, number of awakening and average awaken time)

  5. Treatment response rate [After completion of the 12 weeks intervention]

    The percentage of participants that have their Score of Pittsburgh Sleep Quality Index reduced by at least 5 points

  6. Body composition [After completion of the 12 weeks intervention]

    Body lean mass, fat mass, and bone density will be measured by dual-energy X-ray absorptiometry

  7. Maximal oxygen consumption [After completion of the 12 weeks intervention]

    Metabolic cart will measure the maximal oxygen consumption during the maximal exercise test

  8. Anxiety level [After completion of the 12 weeks intervention]

    Anxiety level will be measured by HASD and General Anxiety Disorder-7.

  9. Severity of depression [After completion of the 12 weeks intervention]

    PHQ-9 will be used to examine the severity of depression.

  10. Blood chemistry tests [After completion of the 12 weeks intervention]

    biological markers related to depression and sleep will be measured by enzyme-linked immunosorbent assa

  11. Subjectively measured quality of life [After completion of the 12 weeks intervention]

    Measured by the 12-item Short Form Survey, scores range from 0 to 100, higher scores indicating better physical and mental health functioning

  12. Enjoyment of exercise intervention [After completion of the 12 weeks intervention]

    Physical activity enjoyment scale will be used to test the subject's perception of the exercise, higher scores reflect greater levels of enjoyment

  13. Attention level [After completion of the 12 weeks intervention]

    Computer attention test in PsychoPy v2 software will be employed to measure the attention.

  14. Habitual physical activity [After completion of the 12 weeks intervention]

    Habitual physical activity will be measured by IPAQ

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. borderline abnormal depression with score above 8 out of 21 on Hospital Anxiety and Depression Scale (HADS),

  2. chronic insomnia according to the fifth edition of the diagnostic and statistical manual of mental disorder (DSM-5),

  3. Cantonese, Mandarin or English speaking, and 4) age 50 or above. To enhance generalizability, males and females will be recruited.

Exclusion Criteria:
  1. contraindications to participating in physical exercise;

  2. regular exercise habit in the past three months (i.e.,>75 minutes of vigorous-intensity exercise weekly or >150 minutes of moderate-intensity exercise weekly);

  3. any pre-existing medical or physical issues that affect the experimental test and exercise intervention;

  4. diagnosis with psychosis, schizophrenia or bipolar disorder;

  5. currently receiving non-medication treatment for depression or insomnia, such as mindfulness training or cognitive behavior therapy;

  6. shift worker or other commitment that interferes with the regular sleep pattern at night; and

  7. abnormal heart's electrical activity according to the exercise electrocardiography (ECG) test, such as irregular heartbeat, arrhythmia, and myocardial infarction.

Contacts and Locations

Locations

Site City State Country Postal Code
1 LKS Faculty of Medicine Hong Kong Hong Kong

Sponsors and Collaborators

  • The University of Hong Kong

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The University of Hong Kong
ClinicalTrials.gov Identifier:
NCT04354922
Other Study ID Numbers:
  • DI
First Posted:
Apr 21, 2020
Last Update Posted:
Feb 1, 2022
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by The University of Hong Kong
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 1, 2022